Sofía Braga

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Rashmi K. Murthy, Sherene Loi, Alicia Okines et al. · New England Journal of Medicine · 2019 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +12

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

José Baselga, Patricia Gómez, Richard Greil et al. · Journal of Clinical Oncology · 2013 · 351 citations · Full text

Medicine, Oncology, Pharmacology +17

Global cancer control: responding to the growing burden, rising costs and inequalities in access

Sofía Braga, Branislav Bystrický, Camilla Qvortrup et al. · ESMO Open · 2018 · 314 citations · Full text

Public Health, Health Policy, Oncology +17

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial

José Manuel Pérez-García, Marta Vaz Batista, Patricia Cortez et al. · Neuro-Oncology · 2022 · 248 citations · Full text

Medicine, Oncology, Pharmacology +17